NeuroOne Medical Technologies To Restate Q1 2026 Financial Statements; Restatement Corrects $0.5M Revenue Overstatement For Q1 2026; Net Loss Understated By $0.3M For Q1 2026; Restatement Does Not Affect Fy2026 Product Revenue Guidance Or Cash Position